Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
>
Insights >
Fc receptor affinity testing to support the therapeutic antibody development An antibody is also known as an immunoglobulin (Ig). It is a large Y-shape protein produced mainly by plasma cells. In general, antibody consists of two identical light chains and two identical heavy chains, connected by disulfide bonds. There are five types of mammalian Ig heavy chain, and the type of heavy chain present defines the class of antibody, IgA, IgD, IgE, IgG, and IgM antibody, respectively.
Fig. 1 Five different classes of antibody
IgG is the most common type of antibody found in blood circulation, which is about 10 to 20% of the total plasma proteins. IgG is also the main type of antibody among the five classes, representing approximately 75% of serum antibodies. There are four IgG subclasses in humans: IgG1, 2, 3, and 4, named in order of their abundance in serum. These four IgG subclasses are similar in structure, consisting of Fab region (variable), hinge region, and Fc region (constant).
Fig. 2 Four IgG subclasses
Since the launch of OKT-3 in 1986, more and more therapeutic antibodies are in clinical use. Antibody drugs become an effective target treatment against cancer, infectious diseases, and autoimmune diseases.
Bioengineering technology advanced a lot during the past few decades. Researchers spend great efforts to study the structure-activity relationship of antibodies. The engineering of the Fc regions is one of the most common parts. The Fc region interacts with Fc receptors and some proteins of the complement system allowing antibodies to activate the immune system. Thus, during drug development, it is critical to developing an assay, measuring the interaction of the Fc region of antibodies and the Fc receptors. As the global antibody market getting competitive, how to design a different and superior product is going to be the key. Besides the screening of the antibodies binding different epitopes, Fc region engineering is a good method to develop competitive products by means of optimizing the biological effects and half-life of antibodies.
Fc receptors can specifically bind to the Fc region of the immunoglobulins. Currently, FcRn and FcγR are the two most common tested Fc receptors. As we mentioned before, the interaction between antibodies and Fc receptors can not only affect the half-life but also induce the immune responses including Antibody-dependent cell-mediated cytotoxicity (ADCC), Complement-Dependent Cytotoxicity (CDC), and phagocytosis. The Fc region engineering will change the antibody affinity to the Fc receptors and then change ADCC or CDC effect. Therefore, it is an important project to optimize the Fc region.
ACROBiosystems developed over 50 high-quality Fc receptor proteins with different tags or from different species to support the antibody structural research. With a strong team of scientists, ACROBiosystems also provides high-quality integrated SPR&BLI analytical services. ACRO has served and collaborated with more than 100 customers from academia and industry. Our work supported multiple antibody drugs IND applications.
Click to learn more about SPR /BLI analytical service
All Fc receptor proteins needed are free of charge, If you have requirements, please contact us
All Fc receptor proteins needed are free of charge
Only provide analytes, then get the full service
Case study
The affinity performance of different IgG antibody subtypes to FcRn receptor-SPR
Affinity analysis based on the development of non-mutated IgG1 and human FcγR molecules of different genotypes—SPR
This web search service is supported by Google Inc.